CARM Carisma Therapeutics
- 0.440
- +0.021+5.09%
Carisma Therapeutics News
H.C. Wainwright Downgrades Carisma Therapeutics(CARM.US) to Hold Rating
CARISMA Therapeutics Analyst Ratings
D. Boral Capital Maintains Buy on CARISMA Therapeutics, Maintains $12 Price Target
Carisma Therapeutics Cut to Neutral From Outperform by Baird
Carisma Therapeutics Price Target Cut to $1.00/Share From $10.00 by Baird
Baird Downgrades Carisma Therapeutics(CARM.US) to Hold Rating, Cuts Target Price to $1
BTIG Maintains Carisma Therapeutics(CARM.US) With Hold Rating
Carisma Therapeutics: Hold Rating Amid Strategic Shift and Uncertain Pipeline Prospects
Carisma Therapeutics Cut to In-Line From Outperform by Evercore ISI Group
Evercore Downgrades Carisma Therapeutics(CARM.US) to Hold Rating, Cuts Target Price to $0.7
BTIG Downgrades Carisma Therapeutics(CARM.US) to Hold Rating
CARISMA Therapeutics Analyst Ratings
Carisma Therapeutics Price Target Maintained With a $24.00/Share by D. Boral Capital
Carisma Therapeutics Is Maintained at Buy by D. Boral Capital
Optimistic Buy Rating for Carisma Therapeutics Amid Promising CAR-Myeloid Developments and Strong Financial Standing
Evercore Maintains Carisma Therapeutics(CARM.US) With Buy Rating, Maintains Target Price $4
Evercore ISI Remains a Buy on Carisma Therapeutics (CARM)
CARISMA Therapeutics Analyst Ratings
EF Hutton Maintains Buy on CARISMA Therapeutics, Maintains $24 Price Target
EF Hutton Initiates Coverage On CARISMA Therapeutics With Buy Rating, Announces Price Target of $24
No Data